Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: It remains controversial whether hormone therapy in recently postmenopausal women modifies the risk of Alzheimer's disease (AD). OBJECTIVE: To investigate the effects of hormone therapy on amyloid-β deposition in recently postmenopausal women. METHODS: Participants within 5-36 months past menopause in the Kronos Early Estrogen Prevention Study, a randomized, double blinded placebo-controlled clinical trial, were randomized to: 1) 0.45 mg/day oral conjugated equine estrogens (CEE); 2) 50μg/day transdermal 17β-estradiol; or 3) placebo pills and patch for four years. Oral progesterone (200 mg/day) was given to active treatment groups for 12 days each month. 11C Pittsburgh compound B (PiB) PET imaging was performed in 68 of the 118 participants at Mayo Clinic approximately seven years post randomization and three years after stopping randomized treatment. PiB Standard unit value ratio (SUVR) was calculated. RESULTS: Women (age = 52-65) randomized to transdermal 17β-estradiol (n = 21) had lower PiB SUVR compared to placebo (n = 30) after adjusting for age [odds ratio (95% CI) = 0.31(0.11-0.83)]. In the APOEɛ4 carriers, transdermal 17β-estradiol treated women (n = 10) had lower PiB SUVR compared to either placebo (n = 5) [odds ratio (95% CI) = 0.04(0.004-0.44)], or the oral CEE treated group (n = 3) [odds ratio (95% CI) = 0.01(0.0006-0.23)] after adjusting for age. Hormone therapy was not associated with PiB SUVR in the APOEɛ4 non-carriers. CONCLUSION: In this pilot study, transdermal 17β-estradiol therapy in recently postmenopausal women was associated with a reduced amyloid-β deposition, particularly in APOEɛ4 carriers. This finding may have important implications for the prevention of AD in postmenopausal women, and needs to be confirmed in a larger sample.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ashburner, J., & Friston, K. J. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.02.018 · Cited by 7,507 · cited 1×
“Cognitive tests scores were compared across the treatment and the placebo groups using ANOVA and Tukey’s honest significant differences test for the post-hoc comparisons with adjustments.”
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“High A deposition measured on PET imaging or via cerebrospinal fluid is considered to be the earliest biomarker change observed during the preclinical stages of AD [27, 28].”
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 1×
“High A β deposition measured on PET imaging or via cerebrospinal fluid is considered to be the earliest biomarker change observed during the preclinical stages of AD [27, 28].”
Self-citationRegression Models for Ordinal Data
McCullagh, P. (1980) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1980.tb01109.x · Cited by 4,453
Jack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958 · cited 1×
“Characteristics of participants were compared across the treatment and the placebo groups using Kruskal-Wallis tests or Fisher exact tests, as appropriate.”
Self-citationPost-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · cited 1×
“PiB retention on PET imaging is a quantitative measure of A β deposition [26].”
Sex modifies the APOE ‐related risk of developing Alzheimer disease
Altmann, A., Tian, L., Henderson, V. W., Greicius, M. D., & Alzheimer's Disease Neuroimaging Initiative Investigators (2014) · Annals of Neurology · doi:10.1002/ana.24135 · Cited by 891
Estrogen use, APOE, and cognitive decline: Evidence of gene–environment interaction
Yaffe, K., Haan, M., Byers, A., Tangen, C., & Kuller, L. (2000) · Neurology · doi:10.1212/wnl.54.10.1949 · Cited by 371 · cited 1×
“On the contrary, APOE 4 positive women had more cognitive decline than APOE 4 negative women if they used hormone therapy (primarily with oral CEE) in two other observational studies [37, 38].”
Rocca, W. A., Grossardt, B. R., & Shuster, L. T. (2011) · Brain Research · doi:10.1016/j.brainres.2010.10.031 · Cited by 283 · cited 1×
“Although determining the effects of hormone treatment shortly after menopause on the risk of dementia would require decades of follow-up, non-invasive imaging markers of Alzheimer’s disease (AD) pathophysiology can potentially assess the efficacy of preventive interventions in the short term.”
Self-citationCORDER, E. H., GHEBREMEDHIN, E., TAYLOR, M. G., THAL, D. R., OHM, T. G., & BRAAK, H. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1297.005 · Cited by 254 · cited 1×
“APOE 4 carriers have increased A deposition at an earlier age than APOE 4 non-carriers, and this difference is more pronounced in women than in men [32, 33].”
Sex and gender differences in the causes of dementia: A narrative review
Rocca, W. A., Mielke, M. M., Vemuri, P., & Miller, V. M. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.05.008 · Cited by 186 · cited 1×
“Carriers of the APOE 4 allele are at an increased risk of AD dementia; moreover the risk may be higher in women than in men [30, 31].”
Self-citationPostmenopausal hormone therapy, timing of initiation, APOE and cognitive decline
Kang, J. H., & Grodstein, F. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.10.007 · Cited by 90 · cited 1×
“On the contrary, APOE 4 positive women had more cognitive decline than APOE 4 negative women if they used hormone therapy (primarily with oral CEE) in two other observational studies [37, 38].”
Cited by
Understanding the impact of sex and gender in Alzheimer’s disease: A call to action
Nebel, R. A., Aggarwal, N. T., Barnes, L. L., Gallagher, A., Goldstein, J. M., Kantarci, K., Mallampalli, M. P., Mormino, E. C., Scott, L., Yu, W. H., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.04.008 · Cited by 839
Self-citationThe Role of Estrogen in Brain and Cognitive Aging
Russell, J. K., Jones, C. K., & Newhouse, P. A. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00766-9 · Cited by 257
Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment
Flores, V. A., Pal, L., & Manson, J. E. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab011 · Cited by 174
The Interaction Between NF-κB and Estrogen in Alzheimer’s Disease
Mishra, P., Davies, D. A., & Albensi, B. C. (2023) · Molecular Neurobiology · doi:10.1007/s12035-022-03152-3 · Cited by 51
“Moreover, it was found that apoE4 carriers also have a reduction of Aβ deposits in postmenopausal women after receiving E2 treatment [103].”
BackgroundSchwarz, K. G., Vicencio, S. C., Inestrosa, N. C., Villaseca, P., & Del Rio, R. (2024) · The Journal of Physiology · doi:10.1113/jp285126 · Cited by 40
Metadata
- Authors
- Kantarci, K., Lowe, V. J., Lesnick, T. G., Tosakulwong, N., Bailey, K. R., Fields, J. A., Shuster, L. T., Zuk, S. M., Senjem, M. L., Mielke, M. M., Gleason, C., Jack, C. R., Rocca, W. A., & Miller, V. M.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2016-07-13
- Volume
- 53
- Issue
- 2
- Pages
- 547-556
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2378845778
- Cited by
- 122
- References
- 12
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.